DARE Q3'26 Earnings: EPS estimate is (0.13) USD

Dare Bioscience (DARE) will report Q3'26 earnings on November 16. Analysts expect $2.04M revenue and a loss of $0.13 per share. Results will be released after market close.

Original reporting
Published Nov 13, 2026, 12:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 13, 2026, 12:12 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
DARE Q3'26 Earnings: EPS estimate is (0.13) USD — source image
Decision brief

The 30-second read

$DAREBearishLow
01

Why it matters

The negative EPS estimate sets expectations for a loss, likely prompting short‑term selling ahead of the earnings call.

02

Market read

The earnings preview provides new guidance for a small-cap biotech, offering limited but actionable insight for traders focused on micro‑caps.

03

What to watch

Potential upcoming clinical trial data or partnership announcements could offset the weak guidance.

Relevance 6/10Novelty 5/10Timing: pre‑market on November 16

Background

Dare Bioscience is a micro‑cap biotech listed on Nasdaq under the ticker DARE.

Company-level read

Ticker impact

$DAREBearishMedium confidence
Context

Dare Bioscience announced its Q3'26 earnings estimate of (0.13) EPS and $2.04M revenue, the first public disclosure of these numbers.

Expected impact

likely downside pressure as investors price in the negative EPS forecast

Evidence & confidence

The forecast shows a loss per share; historically such guidance leads to short-term sell pressure before the earnings call.

Market effects

Biotech sector may see modest pullback as a micro‑cap reports a loss forecast.

US small‑cap biotech segment could face slight negative sentiment.

Limited to investors tracking micro‑cap earnings; no broader market effect.

Counterpoint

If the company surprises to the upside, the stock could rally sharply from a low base.

Key entities

  • Dare Bioscience, Inc.

    Biotech firm reporting Q3'26 earnings estimate.

Related articles

$DAREMed

Daré Bioscience Reports Third Quarter 2026 Financial Results and Highlights Commercial Execution and Pipeline Advancement

Dare Bioscience, Inc. (DARE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Daré Bioscience Reports Third Quarter 2026 Financial Results and Highlights Commercial Execution and Pipeline Advancement DARE to PLAY™ Sildenafil Cream prescription dispensing activities underway this month, with prescriptions written across 48 states and Washington

$DAREMedAI 8/10

Daré Bioscience to Present Phase 1 Sildenafil Cream Data at Sexual Medicine Society of North America (SMSNA) Annual Fall Scientific Meeting

Daré Bioscience (NASDAQ: DARE) will present Phase 1 data on its Sildenafil Cream at the SMSNA Annual Fall Scientific Meeting. The study showed lower systemic exposure compared to oral sildenafil, with no serious adverse events. The company is developing the cream as a potential treatment for female sexual arousal disorder (FSAD), for which there are currently no FDA-approved treatments.

$DAREMedAI 8/10

Daré Bioscience Reports Phase 1 Sildenafil Cream Data Showing Lower Systemic Exposure

Daré Bioscience (DARE) reported Phase 1 data for its Sildenafil Cream, showing lower systemic exposure than oral sildenafil. The study, published in Sexual Medicine, involved 62 healthy men and found significantly lower plasma concentrations for topical administration. The cream is being developed for women's sexual health. DARE stock is currently trading at $0.71, up 0.69%.